NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
Clinical Trials
232 trialsNCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT05432492 2026-03-04
A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Akeso
Phase 2 Completed
NCT04945720 2026-02-25
Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT03463876 2026-02-17
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05176223 2026-02-05
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT05641896 2026-01-22
18F-FAPI-74 GI
SOFIE
Phase 2 Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT05349331 2026-01-15
WATCH
Sun Yat-sen University
Phase 2 Completed
NCT03199274 2026-01-02
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
Thomas Jefferson University
Phase 2 Completed
NCT05532319 2025-12-30
FRONT-1
Guangxi Medical University
Phase 2 Completed
NCT04798781 2025-12-11
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04828486 2025-11-18
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT05622071 2025-11-17
HESTIA
UNICANCER
Phase 2 Completed
NCT04762888 2025-10-31
68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT00183885 2025-10-30
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
University of Southern California
Phase 2 Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT03638141 2025-08-17
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05101629 2025-07-23
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT02940496 2025-07-15
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT05750030 2025-05-06
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Medical University of Vienna
Phase 2 Completed
NCT04000737 2025-04-13
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Yiviva Inc.
Phase 2 Completed
NCT04316182 2025-03-30
ACTION
Fundacion Clinic per a la Recerca Biomédica
Phase 2 Completed
NCT04401800 2025-03-10
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Phase 2 Completed
NCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT04297280 2025-02-27
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Completed
NCT05162352 2025-02-12
Donafenib Plus Sintilimab for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Completed
NCT03439891 2025-02-11
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
University of California, San Francisco
Phase 2 Completed
NCT04511455 2025-01-30
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04522908 2025-01-30
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04767906 2025-01-23
CaPture
University of Leipzig
Phase 2 Completed
NCT05302921 2025-01-01
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Phase 2 Completed
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03009461 2024-12-04
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
Peking University
Phase 2 Completed
NCT03606590 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
NovoCure Ltd.
Phase 2 Completed
NCT05003700 2024-11-05
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT03419897 2024-10-26
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
BeiGene
Phase 2 Completed
NCT04011033 2024-10-08
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Beijing YouAn Hospital
Phase 2 Completed
NCT02702414 2024-09-04
KEYNOTE-224
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01752933 2024-08-27
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT05262959 2024-08-13
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Phase 2 Completed
NCT03630640 2024-07-31
NIVOLEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03753659 2024-07-22
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03510871 2024-07-08
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT04518852 2024-06-25
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT06232759 2024-06-10
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT04172571 2024-05-30
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
Akeso
Phase 2 Completed